By Leah Glenn
The University of Alabama at Birmingham Callahan Eye Hospital has been named one of the newest sites for Spark Therapeutics’ Luxturna, the first gene therapy treatment approved by the Food and Drug Administration for a genetic disease.
It is a prescription gene therapy for patients with inherited retinal disease due to mutations in both copies of the RPE65 gene, which can be confirmed only through genetic testing. Patients must have viable retinal cells as determined by the treating physicians.
The AlabamaWx Weather Blog gladly brings you an excerpt of this article through a partnership with the Alabama NewsCenter. You can see the complete post featuring all the associated images, videos, and links by clicking HERE.
Alabama News Center
All news and articles are copyrighted to the respective authors and/or News Broadcasters. LC is an independent Online News Aggregator
Read more from original source here…